Orexigen Therapeutics

Orexigen Therapeutics is a public American pharmaceutical company focused on development of treatments for obesity.[1] The company is based in La Jolla, California and was established by Eckard Weber in 2002.[1] As a public company, Orexigen is traded on the NASDAQ exchange under the stock symbol OREX.[1]

Orexigen Therapeutics, Inc.
TypePublic
Founded2002 (2002)
FounderEckard Weber
HeadquartersLa Jolla, California, U.S.
Websitewww.orexigen.com

The company has a single product, Contrave, approved for use in the United States in 2014.[2][3] Contrave was designed not only to curb hunger but also reduce cravings.[3] Observation of the market performance of Qsymia and Belviq suggest overall low demand for pharmaceutical obesity therapies, calling into question earnings potential for Orexigen's offering.[2]

Orexigen declared bankruptcy in 2018 and was sold to Nalpropion.[4][5]

References


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.